Symbols / CRVO Stock $4.05 +2.79% CervoMed Inc.
CRVO (Stock) Chart
About
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Stock Fundamentals
Scroll to Statements| Market Cap | 37.50M | Enterprise Value | 15.61M | Income | -26.97M | Sales | 4.01M | Book/sh | 1.97 | Cash/sh | 2.25 |
| Dividend Yield | — | Payout | 0.00% | Employees | 15 | IPO | — | P/E | — | Forward P/E | -2.39 |
| PEG | — | P/S | 9.36 | P/B | 2.06 | P/C | — | EV/EBITDA | — | EV/Sales | 3.90 |
| Quick Ratio | 4.57 | Current Ratio | 4.91 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -2.98 | EPS next Y | -1.69 |
| EPS Growth | — | Revenue Growth | -99.60% | Earnings | 2026-05-07 | ROA | -53.62% | ROE | -93.92% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | -954.79% | Profit Margin | 0.00% | Shs Outstand | 9.26M | Shs Float | 6.29M | Short Float | 4.89% |
| Short Ratio | 4.56 | Short Interest | — | 52W High | 13.13 | 52W Low | 3.51 | Beta | -5.04 | Avg Volume | 78.85K |
| Volume | 6.23K | Target Price | $22.14 | Recom | Strong_buy | Prev Close | $3.94 | Price | $4.05 | Change | 2.79% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$22.14
Mean price target
2. Current target
$4.05
Latest analyst target
3. DCF / Fair value
$-25.88
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.05
Low
$11.00
High
$31.00
Mean
$22.14
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-23 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2026-04-22 | main | D. Boral Capital | Buy → Buy | $31 |
| 2026-04-08 | main | D. Boral Capital | Buy → Buy | $31 |
| 2026-03-19 | main | D. Boral Capital | Buy → Buy | $31 |
| 2026-03-18 | main | Roth Capital | Buy → Buy | $11 |
| 2026-03-18 | main | Chardan Capital | Buy → Buy | $21 |
| 2026-03-16 | main | D. Boral Capital | Buy → Buy | $31 |
| 2026-03-05 | main | Chardan Capital | Buy → Buy | $15 |
| 2026-03-04 | main | D. Boral Capital | Buy → Buy | $31 |
| 2026-02-18 | main | D. Boral Capital | Buy → Buy | $31 |
| 2025-12-18 | init | Cantor Fitzgerald | — → Overweight | — |
| 2025-12-18 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-12-05 | main | D. Boral Capital | Buy → Buy | $31 |
| 2025-12-02 | main | D. Boral Capital | Buy → Buy | $31 |
| 2025-11-11 | main | D. Boral Capital | Buy → Buy | $31 |
| 2025-11-05 | up | HC Wainwright & Co. | Neutral → Buy | $25 |
| 2025-11-04 | main | D. Boral Capital | Buy → Buy | $31 |
| 2025-09-08 | reit | HC Wainwright & Co. | Neutral → Neutral | $11 |
| 2025-08-18 | main | D. Boral Capital | Buy → Buy | $31 |
| 2025-08-12 | reit | Roth Capital | Buy → Buy | $16 |
- Drug candidate boosted brain region tied to Lewy body dementia - Stock Titan Wed, 22 Apr 2026 11
- CRVO Maintained by D. Boral Capital -- Price Target Steady at $3 - GuruFocus hu, 23 Apr 2026 00
- CRVO (CervoMed Inc.) reports wider-than-expected Q4 2025 loss driven by elevated clinical research spending. - Decline Phase - Cổng thông tin điện tử Tỉnh Sơn La Wed, 22 Apr 2026 20
- CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results - TipRanks Wed, 22 Apr 2026 20
- $CRVO stock is down 11% today. Here's what we see in our data. - Quiver Quantitative ue, 02 Dec 2025 08
- Is CervoMed (CRVO) stock a good candidate for diversification (Investor Concern) 2026-04-18 - Community Pattern Alerts - Xã Châu Thành Sat, 18 Apr 2026 22
- CervoMed (NASDAQ:CRVO) Will Have To Spend Its Cash Wisely - simplywall.st Wed, 18 Feb 2026 08
- CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance Fri, 13 Mar 2026 07
- CervoMed (CRVO) Shows Promise in DLB Treatment with Neflamapimod - GuruFocus Wed, 22 Apr 2026 15
- $CRVO stock is up 11% today. Here's what we see in our data. - Quiver Quantitative Mon, 17 Nov 2025 08
- A blood test flagged which Lewy body dementia patients benefited more - Stock Titan hu, 19 Mar 2026 07
- CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance Fri, 07 Nov 2025 08
- Dementia drug CervoMed readies 2026 trials on six‑month cash runway - Stock Titan ue, 17 Mar 2026 07
- AWM-owned funds hold 405,165 shares in CervoMed (CRVO) — 4.2% stake - Stock Titan ue, 07 Apr 2026 07
- CervoMed picks 50mg dose for dementia drug after Phase 1 study - Stock Titan Wed, 04 Mar 2026 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
28.29
+55.23%
|
18.23
+133.30%
|
7.81
+124.80%
|
3.48
|
| Research And Development |
|
21.82
+16.06%
|
18.80
+122.77%
|
8.44
+531.40%
|
1.34
|
| Selling General And Administration |
|
10.48
+14.37%
|
9.17
+40.61%
|
6.52
+204.77%
|
2.14
|
| General And Administrative Expense |
|
10.48
+14.37%
|
9.17
+40.61%
|
6.52
+204.77%
|
2.14
|
| Other Gand A |
|
10.48
+14.37%
|
9.17
+40.61%
|
6.52
+204.77%
|
2.14
|
| Other Operating Expenses |
|
-4.01
+58.86%
|
-9.74
-36.29%
|
-7.14
|
—
|
| Total Expenses |
|
28.29
+55.23%
|
18.23
+133.30%
|
7.81
+124.80%
|
3.48
|
| Operating Income |
|
-28.29
-55.23%
|
-18.23
-133.30%
|
-7.81
-124.80%
|
-3.48
|
| Total Operating Income As Reported |
|
-28.29
-55.23%
|
-18.23
-133.30%
|
-7.81
-124.80%
|
-3.48
|
| EBITDA |
|
-28.29
-55.23%
|
-18.23
-133.30%
|
-7.81
-34.65%
|
-5.80
|
| Normalized EBITDA |
|
-28.29
-55.23%
|
-18.23
-133.30%
|
-7.81
-34.65%
|
-5.80
|
| Reconciled Depreciation |
|
—
|
—
|
—
|
0.00
|
| EBIT |
|
-28.29
-55.23%
|
-18.23
-133.30%
|
-7.81
-34.65%
|
-5.80
|
| Total Unusual Items |
|
—
|
—
|
—
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
0.00
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Impairment Of Capital Assets |
|
—
|
—
|
—
|
0.00
|
| Net Income |
|
-26.97
-65.53%
|
-16.29
-650.08%
|
-2.17
+62.57%
|
-5.80
|
| Pretax Income |
|
-26.97
-65.53%
|
-16.29
-650.08%
|
-2.17
+62.57%
|
-5.80
|
| Net Non Operating Interest Income Expense |
|
1.34
-31.00%
|
1.94
+782.94%
|
0.22
+255.99%
|
0.06
|
| Interest Expense Non Operating |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Net Interest Income |
|
1.34
-31.00%
|
1.94
+782.94%
|
0.22
+255.99%
|
0.06
|
| Interest Expense |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Interest Income Non Operating |
|
1.34
-31.00%
|
1.94
+782.94%
|
0.22
+252.63%
|
0.06
|
| Interest Income |
|
1.34
-31.00%
|
1.94
+782.94%
|
0.22
+252.63%
|
0.06
|
| Other Income Expense |
|
-0.01
-740.26%
|
-0.00
-100.02%
|
5.42
+326.93%
|
-2.39
|
| Other Non Operating Income Expenses |
|
-0.01
-740.26%
|
-0.00
-100.02%
|
5.42
+326.93%
|
-2.39
|
| Tax Provision |
|
—
|
—
|
—
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-26.97
-65.53%
|
-16.29
-650.08%
|
-2.17
+62.57%
|
-5.80
|
| Net Income From Continuing Operation Net Minority Interest |
|
-26.97
-65.53%
|
-16.29
-650.08%
|
-2.17
+62.57%
|
-5.80
|
| Net Income From Continuing And Discontinued Operation |
|
-26.97
-65.53%
|
-16.29
-650.08%
|
-2.17
+62.57%
|
-5.80
|
| Net Income Continuous Operations |
|
-26.97
-65.53%
|
-16.29
-650.08%
|
-2.17
+62.57%
|
-5.80
|
| Normalized Income |
|
-26.97
-65.53%
|
-16.29
-650.08%
|
-2.17
+62.57%
|
-5.80
|
| Net Income Common Stockholders |
|
-26.97
-65.53%
|
-16.29
-650.08%
|
-2.17
+62.57%
|
-5.80
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
—
|
—
|
| Diluted EPS |
|
-2.98
-47.52%
|
-2.02
-146.34%
|
-0.82
+92.68%
|
-11.20
|
| Basic EPS |
|
-2.98
-47.52%
|
-2.02
-146.34%
|
-0.82
+92.68%
|
-11.20
|
| Basic Average Shares |
|
9.04
+12.00%
|
8.07
+203.34%
|
2.66
+413.65%
|
0.52
|
| Diluted Average Shares |
|
9.04
+12.00%
|
8.07
+203.34%
|
2.66
+413.65%
|
0.52
|
| Diluted NI Availto Com Stockholders |
|
-26.97
-65.53%
|
-16.29
-650.08%
|
-2.17
+62.57%
|
-5.80
|
| Depreciation Amortization Depletion Income Statement |
|
—
|
—
|
—
|
0.00
|
| Depreciation And Amortization In Income Statement |
|
—
|
—
|
—
|
0.00
|
| Depreciation Income Statement |
|
—
|
—
|
—
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
22.88
-46.89%
|
43.08
+332.00%
|
9.97
+139.86%
|
4.16
|
| Current Assets |
|
22.88
-46.89%
|
43.08
+332.34%
|
9.96
+139.67%
|
4.16
|
| Cash Cash Equivalents And Short Term Investments |
|
20.86
-46.39%
|
38.92
+399.46%
|
7.79
+90.37%
|
4.09
|
| Cash And Cash Equivalents |
|
8.24
-8.49%
|
9.00
+15.48%
|
7.79
+90.37%
|
4.09
|
| Cash Equivalents |
|
—
|
—
|
7.79
+90.37%
|
4.09
|
| Cash Financial |
|
—
|
—
|
—
|
1.59
|
| Other Short Term Investments |
|
12.63
-57.79%
|
29.92
|
0.00
-100.00%
|
12.41
|
| Receivables |
|
0.43
-81.06%
|
2.25
+146.26%
|
0.92
|
0.00
|
| Other Receivables |
|
0.43
-81.06%
|
2.25
+146.26%
|
0.92
|
—
|
| Prepaid Assets |
|
1.27
-33.50%
|
1.91
+51.64%
|
1.26
+1859.39%
|
0.06
|
| Current Deferred Assets |
|
0.32
|
0.00
|
—
|
—
|
| Other Current Assets |
|
—
|
—
|
—
|
0.11
|
| Total Non Current Assets |
|
0.00
|
0.00
-100.00%
|
0.01
|
0.00
|
| Net PPE |
|
—
|
—
|
—
|
—
|
| Gross PPE |
|
—
|
—
|
—
|
—
|
| Goodwill And Other Intangible Assets |
|
—
|
—
|
—
|
—
|
| Other Non Current Assets |
|
—
|
—
|
0.01
|
—
|
| Total Liabilities Net Minority Interest |
|
4.66
+20.03%
|
3.88
+49.45%
|
2.60
-93.07%
|
37.44
|
| Current Liabilities |
|
4.66
+20.03%
|
3.88
+49.45%
|
2.60
-80.27%
|
13.16
|
| Payables And Accrued Expenses |
|
3.51
+18.61%
|
2.96
+99.87%
|
1.48
+292.34%
|
0.38
|
| Payables |
|
1.49
-3.69%
|
1.55
+98.22%
|
0.78
+704.64%
|
0.10
|
| Accounts Payable |
|
1.45
-3.79%
|
1.51
+128.15%
|
0.66
+580.84%
|
0.10
|
| Current Accrued Expenses |
|
2.02
+43.18%
|
1.41
+101.73%
|
0.70
+149.16%
|
0.28
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.06
+32.19%
|
0.80
-21.72%
|
1.03
+181.83%
|
0.36
|
| Total Tax Payable |
|
0.04
+0.00%
|
0.04
-66.41%
|
0.12
|
0.00
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
12.41
|
| Current Debt |
|
—
|
—
|
—
|
12.41
|
| Other Current Borrowings |
|
—
|
—
|
—
|
12.41
|
| Current Capital Lease Obligation |
|
—
|
—
|
—
|
—
|
| Other Current Liabilities |
|
0.08
-28.05%
|
0.12
+30.71%
|
0.09
-31.72%
|
0.13
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
-100.00%
|
24.29
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
—
|
—
|
| Non Current Deferred Liabilities |
|
—
|
—
|
—
|
—
|
| Non Current Deferred Taxes Liabilities |
|
—
|
—
|
—
|
—
|
| Preferred Securities Outside Stock Equity |
|
—
|
—
|
0.00
-100.00%
|
24.29
|
| Stockholders Equity |
|
18.22
-53.52%
|
39.20
+431.43%
|
7.38
+122.16%
|
-33.29
|
| Common Stock Equity |
|
—
|
—
|
—
|
-33.29
|
| Capital Stock |
|
0.01
+6.32%
|
0.01
+53.37%
|
0.01
+995.37%
|
0.00
|
| Common Stock |
|
0.01
+6.32%
|
0.01
+53.37%
|
0.01
+995.37%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
—
|
| Share Issued |
|
9.25
+6.32%
|
8.70
+53.36%
|
5.67
+317.33%
|
1.36
|
| Ordinary Shares Number |
|
9.25
+6.32%
|
8.70
+53.36%
|
5.67
+317.33%
|
1.36
|
| Additional Paid In Capital |
|
115.91
+5.49%
|
109.87
+77.75%
|
61.81
+225.61%
|
18.98
|
| Retained Earnings |
|
-97.70
-38.12%
|
-70.73
-29.92%
|
-54.44
-4.16%
|
-52.27
|
| Gains Losses Not Affecting Retained Earnings |
|
0.01
-89.65%
|
0.06
|
0.00
+100.00%
|
-0.04
|
| Other Equity Adjustments |
|
0.01
-89.65%
|
0.06
|
—
|
-0.04
|
| Total Equity Gross Minority Interest |
|
18.22
-53.52%
|
39.20
+431.43%
|
7.38
+122.16%
|
-33.29
|
| Total Capitalization |
|
18.22
-53.52%
|
39.20
+431.43%
|
7.38
+122.16%
|
-33.29
|
| Working Capital |
|
18.22
-53.52%
|
39.20
+431.99%
|
7.37
+181.90%
|
-9.00
|
| Invested Capital |
|
18.22
-53.52%
|
39.20
+431.43%
|
7.38
+135.34%
|
-20.87
|
| Total Debt |
|
—
|
—
|
—
|
12.41
|
| Net Debt |
|
—
|
—
|
—
|
8.32
|
| Capital Lease Obligations |
|
—
|
—
|
—
|
—
|
| Net Tangible Assets |
|
18.22
-53.52%
|
39.20
+431.43%
|
7.38
+122.16%
|
-33.29
|
| Tangible Book Value |
|
18.22
-53.52%
|
39.20
+431.43%
|
7.38
+122.16%
|
-33.29
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-23.45
-41.86%
|
-16.53
-121.89%
|
-7.45
-189.57%
|
-2.57
|
| Cash Flow From Continuing Operating Activities |
|
-23.45
-41.86%
|
-16.53
-121.89%
|
-7.45
-189.57%
|
-2.57
|
| Net Income From Continuing Operations |
|
-26.97
-65.53%
|
-16.29
-650.08%
|
-2.17
+62.57%
|
-5.80
|
| Depreciation Amortization Depletion |
|
—
|
—
|
—
|
0.00
|
| Depreciation |
|
—
|
—
|
—
|
—
|
| Depreciation And Amortization |
|
—
|
—
|
—
|
0.00
|
| Pension And Employee Benefit Expense |
|
—
|
—
|
0.00
-100.00%
|
0.13
|
| Stock Based Compensation |
|
1.45
+3.05%
|
1.41
+244.85%
|
0.41
+22.11%
|
0.33
|
| Deferred Tax |
|
—
|
—
|
—
|
0.00
|
| Deferred Income Tax |
|
—
|
—
|
—
|
0.00
|
| Operating Gains Losses |
|
—
|
—
|
—
|
0.13
|
| Unrealized Gain Loss On Investment Securities |
|
—
|
0.00
+100.00%
|
-5.42
-327.05%
|
2.39
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Change In Working Capital |
|
2.92
+763.07%
|
-0.44
-68.60%
|
-0.26
-168.79%
|
0.38
|
| Change In Receivables |
|
1.83
+236.48%
|
-1.34
-46.26%
|
-0.92
|
0.00
|
| Change In Prepaid Assets |
|
0.64
+199.57%
|
-0.64
+46.58%
|
-1.20
-1510.21%
|
0.09
|
| Change In Payables And Accrued Expense |
|
0.77
-50.18%
|
1.54
-16.98%
|
1.85
+528.90%
|
0.29
|
| Change In Accrued Expense |
|
0.83
+20.84%
|
0.69
-46.45%
|
1.29
+497.66%
|
0.22
|
| Change In Payable |
|
-0.07
-107.93%
|
0.85
+50.22%
|
0.57
+614.01%
|
0.08
|
| Change In Account Payable |
|
-0.07
-107.93%
|
0.85
+50.22%
|
0.57
+614.01%
|
0.08
|
| Change In Other Working Capital |
|
-0.31
|
—
|
—
|
—
|
| Investing Cash Flow |
|
18.10
+163.14%
|
-28.66
|
0.00
+100.00%
|
-12.24
|
| Cash Flow From Continuing Investing Activities |
|
18.10
+163.14%
|
-28.66
|
0.00
+100.00%
|
-12.24
|
| Net PPE Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Net Investment Purchase And Sale |
|
18.10
+163.14%
|
-28.66
|
0.00
+100.00%
|
-12.24
|
| Purchase Of Investment |
|
-25.40
+47.19%
|
-48.10
|
0.00
+100.00%
|
-37.99
|
| Sale Of Investment |
|
43.50
+123.77%
|
19.44
|
0.00
-100.00%
|
25.75
|
| Financing Cash Flow |
|
4.59
-90.11%
|
46.40
+316.16%
|
11.15
|
0.00
|
| Cash Flow From Continuing Financing Activities |
|
4.59
-90.11%
|
46.40
+316.16%
|
11.15
|
0.00
|
| Net Common Stock Issuance |
|
4.59
-90.11%
|
46.40
+5628.22%
|
0.81
|
0.00
|
| Proceeds From Stock Option Exercised |
|
—
|
—
|
—
|
0.00
|
| Net Other Financing Charges |
|
—
|
—
|
10.34
|
—
|
| Changes In Cash |
|
-0.76
-163.32%
|
1.21
-67.38%
|
3.70
+243.79%
|
-2.57
|
| Beginning Cash Position |
|
9.00
+15.48%
|
7.79
+90.37%
|
4.09
-38.59%
|
6.67
|
| End Cash Position |
|
8.24
-8.49%
|
9.00
+15.48%
|
7.79
+90.37%
|
4.09
|
| Free Cash Flow |
|
-23.45
-41.86%
|
-16.53
-121.89%
|
-7.45
-189.57%
|
-2.57
|
| Amortization Of Securities |
|
-0.85
+29.13%
|
-1.21
|
0.00
+100.00%
|
-0.21
|
| Common Stock Issuance |
|
4.59
-90.11%
|
46.40
+5628.22%
|
0.81
|
0.00
|
| Issuance Of Capital Stock |
|
4.59
-90.11%
|
46.40
+5628.22%
|
0.81
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.01
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.01
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-22 View
- 8-K2026-04-07 View
- 8-K2026-03-23 View
- 8-K2026-03-19 View
- 8-K2026-03-17 View
- 10-K2026-03-13 View
- 8-K2026-03-04 View
- 8-K2026-02-18 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 8-K2026-01-08 View
- 42025-12-05 View
- 8-K2025-12-05 View
- 42025-11-19 View
- 42025-11-19 View
- 42025-11-19 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|